One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial

Acta Dermato-Venereologica

Volumn 90, Issue 2, 2010, Pages 170-174

  Mandelin, Johanna ^a   Remitz, Anita ^a   Virtanen, Hannele ^a   Reitamo, Sakari ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Atopic dermatitis; Hydrocortisone butyrate; Randomized controlled trial; Recall antigen; Tacrolimus ointment

Indexed keywords

HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; IMMUNOGLOBULIN E; TACROLIMUS;

ADULT; APPLICATION SITE BURNING; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; FOLLICULITIS; HEMATOMA; HUMAN; IMMUNOREACTIVITY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN ATROPHY; SKIN INFECTION; STRIA; TH1 CELL; TH2 CELL;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; BUTYRATES; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; FINLAND; HUMANS; HYDROCORTISONE; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; WATER LOSS, INSENSIBLE; YOUNG ADULT;

EID: 77950195945     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0803     Document Type: Article

References (27)

1. Boguniewicz M, Leung DYM. Atopic dermatitis. J Allergy Clin Immunol 2006; 117: S475-480.
2. Stenger D, Delbruck H, Krumrey K, Zaun H. Standardisierte Recall-antigentestung bei Patienten mit malignem Melanom, endogenen Ekzematikern und Gesunden. Z Hautkr 1983; 58: 293-304.
3. Ellis C, Fradin M, Messana J, Brown M, Siegel M, Hartley H, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
4. Ulrich C, Hackethal M, Meyer T, Geusau A, Nindl I, Ulrich M, et al. Skin infections in organ transplant recipients. J Dtsch Dermatol Ges 2008; 6: 98-105.
5. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996; 61: 715-721.
6. Mandelin J, Remitz A, Virtanen H, Reitamo S. Recall antigen reactions in patients with atopic dermatitis treated with tacrolimus ointment for 1 year. J Allergy Clin Immunol 2008; 121: 777-779.
7. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005; 65: 827-858.
8. Yan J, Chen SL, Wang XL, Zhou W, Wang FS. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol 2008; 25: 117-120.
9. Hanifin JM, Palier AS, Eichenfield L, Clark RA, Korman N, Weinstein G, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53 Suppl 2: S186-S194.
10. Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008; 159: 942-951.
11. Remitz A, Harper J, Rustin M, Goldschmidt W, Palatsi R, van der Valk P, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol 2007; 87: 54-61.
12. Reitamo S, Ortonne JP, Sand C, Bos J, Cambazard F, Bieber T, et al. Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, noncomparative study. Acta Derm Venereol 2007; 87: 406-412.
13. Margolis D, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-295.
14. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-816.
15. Luger TA, Lahfa M, Fölster-Holst R, Gulliver WP, Allen R, Molloy S, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15: 169-178.
16. Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. J Dtsch Dermatol Ges 2008; 6: 548-553.
17. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Fölster-Holst R, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282-1289.
18. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol 1989; 144 Suppl: 13-14.
19. Pinnagoda J, Tupker RA, Agner T, Serup J. Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1990; 22: 164-178.
20. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, De Benedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120: 150-155.
21. Cork MJ, Danby S, Vasilopoulos Y, Moustafa M, MacGowan A, Varghese J, et al. Epidermal barrier dysfunction in atopic dermatitis. In: Reitamo S, Luger TA, Steinhoff M, editors. Textbook of atopic dermatitis. London: Informa Healthcare, 2008: p. 35-57.
22. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105: 860-876.
23. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.
24. Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effect of one-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174-1181.
25. Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999-1006.
26. Laske N, Niggemann B. Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol 2004; 15: 86-88.
27. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol 2006; 118: 209-213.